);

Wattle, A2 Milk strengthen China position

Infant formula supplier The A2 Milk Company and Wattle Health Australia have strengthened their regulatory position in the lucrative Chinese market.

A2 Milk’s application to continue selling its infant formula products in China has been approved by China’s health regulator, the China Food and Drug Administration.

Formula manufacturer Synlait Milk, which has been in partnership with A2 Milk since 2010, submitted the mandatory CFDA application in May.

All infant formula manufacturers must register brands and recipes with the CFDA for products to be imported into China from January 1.

Also, foreign manufacturers must register the canning facility used to blend and pack the products with the Certification and Accreditation Administration of People’s Republic of China.

From January 1, 2018, all infant formula to be sold in China must be manufactured by a facility accredited by the CNCA, and each facility can only register up to three brands.

Wattle Health has completed its $5 million acquisition of a 5 per cent interest in Australian infant formula maker Blend & Pack, which is licensed by the CNCA to produce infant formula for China’s market.

Wattle Health said the acquisition ensured that its infant formula range will be the first brand nominated by Blend & Pack for CFDA approval.

As seen in West Australian, September 29th 2017.